Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder »

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder »

[at noodls] – As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing’s disease[1] In the Phase III trial, most patients experienced … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view

Share this post